Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 29 studies | 45% ± 19% | |
pericyte | 23 studies | 38% ± 18% | |
fibroblast | 19 studies | 30% ± 12% | |
capillary endothelial cell | 15 studies | 46% ± 19% | |
smooth muscle cell | 13 studies | 27% ± 8% | |
endothelial cell of artery | 12 studies | 41% ± 19% | |
vein endothelial cell | 11 studies | 37% ± 17% | |
myofibroblast cell | 10 studies | 29% ± 12% | |
type II pneumocyte | 9 studies | 50% ± 21% | |
connective tissue cell | 9 studies | 21% ± 4% | |
endothelial cell of vascular tree | 8 studies | 31% ± 11% | |
kidney loop of Henle epithelial cell | 6 studies | 46% ± 14% | |
goblet cell | 6 studies | 31% ± 19% | |
epithelial cell | 6 studies | 32% ± 23% | |
secretory cell | 5 studies | 27% ± 8% | |
glomerular endothelial cell | 4 studies | 49% ± 4% | |
kidney distal convoluted tubule epithelial cell | 4 studies | 34% ± 10% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 57% ± 11% | |
type I pneumocyte | 3 studies | 21% ± 6% | |
glial cell | 3 studies | 50% ± 18% | |
ciliated cell | 3 studies | 33% ± 20% | |
endothelial cell of sinusoid | 3 studies | 22% ± 5% | |
basal cell | 3 studies | 23% ± 3% | |
club cell | 3 studies | 35% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 6057.75 | 244 / 245 | 89% | 188.12 | 446 / 502 |
lung | 100% | 14035.29 | 577 / 578 | 85% | 316.51 | 985 / 1155 |
pancreas | 88% | 2234.35 | 290 / 328 | 89% | 151.13 | 159 / 178 |
bladder | 100% | 5244.67 | 21 / 21 | 72% | 154.05 | 363 / 504 |
intestine | 98% | 5043.22 | 951 / 966 | 68% | 67.64 | 358 / 527 |
thymus | 92% | 4895.03 | 599 / 653 | 74% | 196.71 | 447 / 605 |
kidney | 100% | 8824.63 | 89 / 89 | 62% | 85.01 | 559 / 901 |
breast | 90% | 4660.59 | 413 / 459 | 67% | 153.98 | 754 / 1118 |
liver | 99% | 8952.38 | 223 / 226 | 55% | 59.84 | 222 / 406 |
stomach | 78% | 2124.80 | 281 / 359 | 64% | 59.95 | 184 / 286 |
uterus | 75% | 2470.98 | 127 / 170 | 58% | 113.19 | 265 / 459 |
ovary | 88% | 2118.56 | 158 / 180 | 39% | 39.49 | 167 / 430 |
adrenal gland | 64% | 1652.16 | 166 / 258 | 37% | 33.14 | 85 / 230 |
spleen | 100% | 5585.41 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 50.47 | 1 / 1 |
esophagus | 61% | 2006.24 | 880 / 1445 | 37% | 47.18 | 68 / 183 |
heart | 97% | 5943.73 | 833 / 861 | 0% | 0 | 0 / 0 |
adipose | 93% | 7171.09 | 1119 / 1204 | 0% | 0 | 0 / 0 |
muscle | 72% | 1698.57 | 582 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 58% | 1881.99 | 779 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 51% | 137.15 | 23 / 45 |
brain | 9% | 118.80 | 232 / 2642 | 39% | 40.87 | 278 / 705 |
skin | 27% | 490.56 | 481 / 1809 | 6% | 7.75 | 30 / 472 |
lymph node | 0% | 0 | 0 / 0 | 7% | 2.62 | 2 / 29 |
peripheral blood | 0% | 6.05 | 3 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_1903706 | Biological process | regulation of hemopoiesis |
GO_1901224 | Biological process | positive regulation of non-canonical NF-kappaB signal transduction |
GO_0034605 | Biological process | cellular response to heat |
GO_1902806 | Biological process | regulation of cell cycle G1/S phase transition |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0010739 | Biological process | positive regulation of protein kinase A signaling |
GO_1900020 | Biological process | positive regulation of protein kinase C activity |
GO_0006915 | Biological process | apoptotic process |
GO_0002264 | Biological process | endothelial cell activation involved in immune response |
GO_0045746 | Biological process | negative regulation of Notch signaling pathway |
GO_0005730 | Cellular component | nucleolus |
GO_0005886 | Cellular component | plasma membrane |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0005112 | Molecular function | Notch binding |
GO_0005515 | Molecular function | protein binding |
Gene name | TCIM |
Protein name | Transcriptional and immune response regulator (Thyroid cancer protein 1) (TC-1) Alternative protein C8orf4 |
Synonyms | C8orf4 TC1 |
Description | FUNCTION: Seems to be involved in the regulation of cell growth an differentiation, may play different and opposite roles depending on the tissue or cell type. May enhance the WNT-CTNNB1 pathway by relieving antagonistic activity of CBY1 . Enhances the proliferation of follicular dendritic cells . Plays a role in the mitogen-activated MAPK2/3 signaling pathway, positively regulates G1-to-S-phase transition of the cell cycle . In endothelial cells, enhances key inflammatory mediators and inflammatory response through the modulation of NF-kappaB transcriptional regulatory activity . Involved in the regulation of heat shock response, seems to play a positive feedback with HSF1 to modulate heat-shock downstream gene expression . Plays a role in the regulation of hematopoiesis even if the mechanisms are unknown (By similarity). In cancers such as thyroid or lung cancer, it has been described as promoter of cell proliferation, G1-to-S-phase transition and inhibitor of apoptosis . However, it negatively regulates self-renewal of liver cancer cells via suppresion of NOTCH2 signaling . . |
Accessions | Q9NR00 ENST00000315792.5 L8E8Y4 |